Literature DB >> 6969732

Expansion of Fc receptor-bearing T lymphocytes in patients with immunoglobulin G and immunoglobulin A myeloma.

R G Hoover, S Hickman, H M Gebel, N Rebbe, R G Lynch.   

Abstract

Lymphocytes obtained from the blood of normal individuals and six patients with newly diagnosed multiple myeloma were separated into T and non-T cell populations by rosette-formation with sheep erythrocytes, and were then assayed for the presence of surface membrane Fc receptors. When compared with normal individuals, four patients with IgG myeloma had a three- to fourfold increase in T cells with IgG receptors (T gamma cells) and two patients with IgA myeloma had a two- to threefold increase in T cells with IgA receptors (T alpha cells). Patients with IgG or IgA myeloma had normal numbers of non-T lymphocytes with surface receptors for IgG and IgA, respectively. The finding that human myeloma is accompanied by elevated numbers of T cells with Fc receptors for the heavy chain class of the myeloma protein: (1) may account for the apparent "monoclonal" lymphocyte population in patients with myeloma; (b) extends to humans similar observations made in mice with secretory plasmacytomas; and (c) is of interest because T cells with Fc receptors are immunoregulatory lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6969732      PMCID: PMC371601          DOI: 10.1172/JCI110028

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  17 in total

1.  Receptors for IgG molecules on human lymphocytes forming spontaneous rosettes with sheep red cells.

Authors:  M Ferrarini; L Moretta; R Abrile; M L Durante
Journal:  Eur J Immunol       Date:  1975-01       Impact factor: 5.532

2.  A receptor for IgA on human T lymphocytes.

Authors:  L G Lum; A V Muchmore; D Keren; J Decker; I Koski; W Strober; R M Blaese
Journal:  J Immunol       Date:  1979-01       Impact factor: 5.422

Review 3.  Characterization of human T-cell subpopulations as defined by specific receptors for immunoglobulins.

Authors:  L Moretta; M Ferrarini; M D Cooper
Journal:  Contemp Top Immunobiol       Date:  1978

4.  Multiple myeloma and benign monoclonal gammopathy: differentiation by immunofluorescence of lymphocytes.

Authors:  F D Lindström; W R Hardy; B J Eberle; R C Williams
Journal:  Ann Intern Med       Date:  1973-06       Impact factor: 25.391

5.  Surface immunoglobulins of circulating lymphocytes in mouse plasmacytoma. I. Characteristics of lymphocyte surface immunoglobulins.

Authors:  V Yakulis; N Bhoopalam; S Schade; P Heller
Journal:  Blood       Date:  1972-04       Impact factor: 22.113

6.  Separation of leukocytes from blood and bone marrow. Introduction.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

7.  The monoclonal nature of lymphocytes in multiple myeloma. Effects of therapy.

Authors:  N I Abdou; N L Abdou
Journal:  Ann Intern Med       Date:  1975-07       Impact factor: 25.391

Review 8.  B and T cell markers in human proliferative blood diseases and primary immunodeficiencies, with special reference to membrane bound immunoglobulins.

Authors:  M Seligmann; J L Preud'Homme; J C Brouet
Journal:  Transplant Rev       Date:  1973

9.  Monoclonal lymphocyte population in human plasma cell myeloma.

Authors:  H Mellstedt; S Hammarström; G Holm
Journal:  Clin Exp Immunol       Date:  1974-07       Impact factor: 4.330

10.  Circulating lymphocytes and the spread of myeloma. Review of the evidence.

Authors:  T F Warner; R G Krueger
Journal:  Lancet       Date:  1978-06-03       Impact factor: 79.321

View more
  20 in total

1.  In vitro inhibition of tumor B cell growth by IgG-BF-producing Fc gamma RII+ T cell hybridoma and by immunoglobulin G-binding factors.

Authors:  C Mathiot; S Amigorena; J Moncuit; C Sautès; W H Fridman; J L Teillaud
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

2.  Multiple myeloma: ecto-5' nucleotidase deficiency of suppressor/cytotoxic (CD8) lymphocytes is a marker for the expansion of suppressor T cells.

Authors:  M Massaia; U Dianzani; P Pioppo; E Sibilla; M Boccadoro; A Pileri
Journal:  Clin Exp Immunol       Date:  1987-08       Impact factor: 4.330

Review 3.  Rous-Whipple Award lecture. The biology and pathology of lymphocyte Fc receptors.

Authors:  R G Lynch
Journal:  Am J Pathol       Date:  1998-03       Impact factor: 4.307

Review 4.  The biology and pathology of Fc receptors.

Authors:  M Sandor; R G Lynch
Journal:  J Clin Immunol       Date:  1993-07       Impact factor: 8.317

5.  Isotype regulation of antibody production: T-cell hybrids can be selectively induced to produce IgG1 and IgG2 subclass-specific suppressive immunoglobulin-binding factors.

Authors:  I Löwy; C Brezin; C Neauport-Sautes; J Theze; W H Fridman
Journal:  Proc Natl Acad Sci U S A       Date:  1983-04       Impact factor: 11.205

6.  T-cell imbalances in patients with multiple myeloma: an analysis by monoclonal antibodies.

Authors:  C D Platsoucas; H J Hansen; J R Redman; S Berenson; B J Lee; B D Clarkson
Journal:  J Clin Immunol       Date:  1983-07       Impact factor: 8.317

Review 7.  Fc receptor--more answers, more questions.

Authors:  L Fornůsek; V Vĕtvicka
Journal:  Folia Microbiol (Praha)       Date:  1984       Impact factor: 2.099

8.  Functional behaviour and immunological phenotype of circulating B lymphocytes in multiple myeloma. Studies with pokeweed mitogen.

Authors:  M Gobbi; F Caligaris-Cappio; D Campana; P L Tazzari; L Bergui; M Cavo; S Tura
Journal:  Clin Exp Immunol       Date:  1984-12       Impact factor: 4.330

9.  Membrane phenotype and functional behaviour of T lymphocytes in multiple myeloma: correlation with clinical stages of the disease.

Authors:  F Lauria; R Foa; M Cavo; M Gobbi; D Raspadori; M C Giubellino; P L Tazzari; S Tura
Journal:  Clin Exp Immunol       Date:  1984-06       Impact factor: 4.330

10.  Effect of chemotherapy on T-lymphocyte subsets in B-cell proliferative disorders.

Authors:  C A Emmendörffer; W J Pichler
Journal:  Blut       Date:  1985-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.